VRTX Nice C/H ON WEEKLYWe have a very nice Cup & Handle. As you can see the volume is dryup with a tightness in price action
VX1 trade ideas
VRTX (Vertex Pharmaceuticals) Heading HigherVolume Profile shows virtually no volume transacted between current price and $260, so price should arrive at $260 without much trouble.
Vertex Bull Run Strengthens We made it to 240 a share. Next resistance around 256, Once we trade up to 256 then VRTX will retest ATH around 307. Buying volume at good levels, Strong earnings, Monthly MACD showing SERIOUS positive momentum, I'm Riding this trade until I see new ATH's for Vertex!
$VRTX WEAKLY CHART #VERTEX #Stock #Stocks #Stockmarketlooks like is getting ready to lift up , waiting for retest #Stock #Stocks #Stockmarket
VRTX Pop to the UpsideVRTX a great long setup presenting itself. VRTX broke out of descending triangle pattern with volume to the upside, MACD about to cross above zero signaling a big shift in momentum on the weekly timeframe. VRTX looks good to go long on here, I see it grinding up in price at a moderate rate for the next year maybe year and a half. 240 dollars a share soon.
VRTX - Looking strong for 2022 (Weekly)VRTX seems to be strengthening after being weak for awhile. Strong move above weekly 200ma on good volume.
I will buy the jan 2023 300/330c spread, and sell the jan 2023 150/140p spread for hopefully no more than .50
Maybe do some shorter OTM term put spreads against it, as well along the way.
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago.
For me its a very good chance and low price for VRTX.
strong up move with good volume crossing the negative trend
crossed EMA200 and MA200 on daily chart and also on weeky chart
still above EMA200 and MA200 on monthly chart
still in positive trend since 2008
good position in the market
good cashflow for the next years, even if products are failing
Vertex Announces Positive Results From Phase 2 Study of VX-147 iVRTX: Vertex Pharmaceuticals Incorporated
2021-12-01 07:30:00
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
LongAt the close of the GAP. The movement is good. Upside +10%. If there will be a good consolidation - we can look even higher.
❤️ If you find this helpful and want more FREE forecasts in TradingView
. . . . . Please show your support back,
. . . . . . . . Hit the 👍 LIKE button,
. . . . . . . . . . . Drop some feedback below in the comment!
❤️ Your Support is very much 🙏 appreciated!❤️
💎 Want us to help you become a better Stock trader?
Now, It's your turn!
Be sure to leave a comment let us know how do you see this opportunity and forecast.
$VRTX #VERTEXI like this RETEST TO PUSH HIGHER AND MAYBE FILL THE GAP THE ORANGE AREA , The risk reward is so far good
#VRTX [D1] Is Retesting. "A Long Entry"NASDAQ:VRTX Is currently retesting a broken wedge. Next target can be set around 194 where it can get a bit choppy.
VRTX LongAll risks already in price IMO. Short downtrend most probably soon will change to bullish as fundamental improves.
Triger: latest news about ABBV & Galapagos Phase 2 study in CF
VRTX DCA [LONG]VRTX looks good value here going into earnings.
Good chance of a bounce with oversold levels on daily and weekly.
** NOT TRADING OR FINANCIAL ADVICE **
VRTX.Usually after a huge move down into prior untested accumulation I would expect a pop to the upside. I dont see us bouncing here. I really think they just reject this level and continue much lower. I am shorting here even though I dont like to short at support. Risking half a percent or less.
$VRTX HTF ACB LongWeekly Swing Watchlist
Couple great looking opportunities this week, otherwise equities look pretty quite with the broad sell offs we have seen. I am already at full risk after entering two trades last week so I will be sitting on my hands for now.
#1 Main Watch
$VRTX HTF ACB L
Monthly - 0.50 Fib/Decel/50 ema
Weekly - Support/MACD/Double bottom
Daily - Support/MACD/Double bottom/Descending triangle/Decel/Wave 5 completion
LTF - Break out of descending triangle/MACD/Double bottom
Entry - Waiting for 1HR close above 50 ema
RR - 10 (Previous M/W highs)
Management - Long term
Additionally on Watch:
Main:
$PENN Daily IBO L
Other:
6 stocks on this weeks development needed list
23 stocks on monthly watchlist (mostly in Tech & Health Care sectors)
Live Trades:
$OEG - Full Risk
$AMC - 0.5% Profit locked in
$MASS - Full Risk
$VUZI - Full Risk
$Z - Full Risk
VRTX LONG [LONG]VRTX been ranging in this area since its dip - looks to be finding its bottom. Potential for a dip further but like this as a LONG entry with medium and long term price targets as per the chart.
** NOT INVESTMENT OR TRADING ADVICE **
Pull Back Fishingis could go even lower I suppose. Possible double bottom if it holds. Last candle is a spinning top/a candle of indecision.
At this point I would guess it may be undervalued. Just goes down and down and down because I have been watching it for months.
Appears the analysts are extremely bearish on VRTX at this time. That is when I stop and take a closer look sometimes, They could be correct for all I know. Sometimes there are things the big guys know that little guys do not know. Like is VRTX going bankrupt or sumpin? I do not think Cystic Fibrosis is going away as it is a genetic disease, but it is also a primarily Caucasian disease? Perhaps just not socially or politically cool right now since it is a primarily Caucasian disease? Perhaps widening their arena to Sickle Cell anemia research and drugs would help the stock price and the analysts would like the stock/but who knows?/just a thought. Tips appreciated.
Eventually everything hits a highpoint, and everything reaches a low point. The country I live in, has hit a temporary low point.
No recommendation.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Hide
EPS (FWD)
12.28
PE (FWD)
15.32
-
Short Interest
1.95%
Market Cap
$49.65B
Volume
1,375,527
VRTX Pushing lowerThis is a dowsing pick. I have a date of Sept. 17th as some kind of move. I'm under the impression this is going to drop hard then. However, there have been enough instances where I'm expecting a low and it's a high and vice versa. Actually, this is pretty consistently what happens. So, It'll be interesting to see what VRTX does next week, but I do have a lot of negative energy and guidance for readers is that it continues down.
Great setup$VRTX
This sucker is banging a double inside daily with an inside weekly.
EMAs are pretty tight here but the SMAs could tighten up a bit more. Like the band curling while the 50 SMA is up.
VERTEX CAN GO UP Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. Excellent bullish divergence on the monthly. Great time for a long trade on this asset that could attempt a retarget in the $ 240 zone.
TrendyTrades: VRTX Bullish AnalysisChart is pretty self explanatory. Looks like we're do for a push up, watch for confirmation before jumping in.
